Replies to post #539443 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thanks Lykiri, when the questioner asked Dr. Liau about a possible human study that combines DCVax-L + PD-1 + CSF-1R inhibitor, and whether are not UCLA had already done some mouse studies using this, Dr. Liau specifically said the following:

”great question, that is actually our next Spore project, we have a collaboration with BMS on a CSF-1R inhibitor”

Dr. Liau went on to say that “we do have some animals studies that showed a great response”

So, that tells me that the animal / mouse studies have already been completed.

As far as asking about this at the NWBio ASM, I don’t believe that NWBio is part of this collaboration because they are not providing any funding, nor are they producing any of the DCVax-L through CRL. I believe all of the DCVax-L was produced in the UCLA GMP lab on campus. So, I don’t believe Linda Powers will answer any questions related to this study.

However, I do believe that NWBio will be the Sponsor of the Phase III registrational DCVax-L + PD-1 inhibitor + CSF-1R inhibitor combo trial after DCVax-L is approved in the US, Canada, UK, Germany and the rest of the EU.